drugset / Trial / NCT03733574
A Study of LY03005 vs Pristiq
RandomizedCrossoverOpen-labelTreatment
Summary
The objective of this study is to evaluate relative bioavailability between 80 mg LY03005 oral tablets and 50 mg Pristiq® oral tablets after a single dose of each drug in a cross-over 2-period design under fasting condition in healthy subjects between 18 and 50 years of age.
Timeline
- Start
- 2018-06-19
- Primary completion
- 2018-07-17
- Completion
- 2018-07-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Desvenlafaxine | Other / unclassified | 50 mg | Oral |
| Subject | Toludesvenlafaxine | Small molecule | 80 mg | Oral |